Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ: BNTX )

98.85 +0.46 (+0.47%)
Streaming Delayed Price Updated: 2:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
66 67 Next >
Woodstock For Capitalists
Good Morning Everyone! Regional bank PacWest is up 34% in pre-market after being up 81% Friday. They slashed their dividend to conserve capital. With a 19% short interest on the stock, there is... 
Via Benzinga
WHO Ends Global Emergency Status for COVID-19, Virgin Galactic Plans To Launch Space Tourism In Q2, Berkshire Hathaway Has No Intentions To Take Control Of Occidental Petroleum: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations
The launch of an updated booster could increase demand. 
Via Investor's Business Daily
Despite Continuous Dip In Covid-19 Vaccine Sales, BioNTech Manages To Post Q1 Profit, Reaffirms Guidance
BioNTech SE (NASDAQ: BNTX) reported Q1 FY23 revenues of €1.28 billion, down from €6.37 billion a year ago, mainly due to lower commercial revenues from the supply and sales of the 
Via Benzinga
Earnings Preview For BioNTech
Via Benzinga
How To Attend BioNTech Q1 2023 Earnings Conference Call
Via Benzinga
Buy This Pharma Powerhouse With A 4% Yield
Imagine a company whose stock hit an all-time in December 2021 after soaring 50% that year. And that company’s sales doubled in the two years leading up to 2022. And its operating profits quadrupled. 
Via Talk Markets
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns
The World Health Organization ended the global emergency 
Via Benzinga
US Stocks Set For Mixed Start This Week On Inflation, Debt Ceiling Worries — But Analyst Sees A 'Turning Point'
Caution returned to Wall Street as indicated by the index futures, which traded narrowly mixed early Monday. 
Via Benzinga
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
P/E Ratio Insights for BioNTech
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
What 12 Analyst Ratings Have To Say About BioNTech
Via Benzinga
A Look Into BioNTech Inc's Price Over Earnings
Via Benzinga
The 7 Best Bargain Stocks to Buy for May 2023
With inflation crimping everyone’s wallet, these best bargain stocks to buy can make your dollars stretch significantly. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
From BioNTech SE
Via GlobeNewswire
Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?
The company is facing a litigation headwind and continued competition. 
Via Investor's Business Daily
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
Make your dollars go as far as possible (and relatively safely) with these low-PE ratio blue-chip stocks to buy. 
Via InvestorPlace
FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid
Via Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Via Benzinga
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
From BioNTech SE
Via GlobeNewswire
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica. 
Via Investor's Business Daily
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.